Vasculitis & polymyalgia rheumatica

Cardiac involvement in eosinophilic granulomatosis with polyangiitis: acute eosinophilic myocarditis and chronic inflammatory cardiomyopathy

Rheumatology (Oxford)Published Retrospective cohort study

Authors' conclusion

We first proposed different subtypes of cardiac involvement in EGPA. Identification and treatment of EGPA-EM needs improvement. LATE-EAST score could recognize the high-risk EGPA-EM effectively.

Study context

Population
Eosinophilic granulomatosis with polyangiitis (EGPA) patients hospitalized in one centre 2012–2023 and in public databases118 with cardiac involvement
Participants
193 patients
Exposure
EGPA-EM vs EGPA-ICM vs EGPA-Control
  • EGPA-EMn = 74
  • EGPA-ICMn = 44
  • EGPA-Controln = 75reference
Outcome
Clinical and laboratory features across groups
Methodological detailssingle-centre and public database cases
  • Single-centre and public database cases

Main finding

As reported in the abstract

Eosinophils, EGPA-Control/EGPA-ICM/EGPA-EM (× 109/l), P < 0.01
6.12/8.71/10.42
ANCA positivity, EGPA-Control/EGPA-ICM/EGPA-EM, P < 0.01
41.33/31.82/14.86%
Lung involvement, EGPA-Control/EGPA-ICM/EGPA-EM, P = 0.02
73.33/72.73/43.24%
Cardiac troponin (ng/ml), EGPA-ICM vs EGPA-EM, P < 0.01
0.27 vs 6.00
Ejection fraction, EGPA-ICM vs EGPA-EM, P < 0.01
57.79 vs 33.20%
ST-T abnormality, EGPA-EM vs EGPA-ICM, P = 0.02
41.89 vs 20.45%

Observational data: associations, not effects.

Further findings

Prognosis of EGPA-EM
14.86%
  • LATE-EAST diagnostic score (7 items, 9 points; threshold 4 points) to discriminate EGPA-EM from EGPA-ICM: LATE-EAST score AUC 0.85 (95% CI 0.78-0.92) · sensitivity 0.78 · specificity 0.86

Prognosis of EGPA-EM

Prognosis of EGPA-EM significantly worse; 2-year event-free survival rate below 50%

Original publication

Cardiac involvement in eosinophilic granulomatosis with polyangiitis: acute eosinophilic myocarditis and chronic inflammatory cardiomyopathy. Rheumatology (Oxford). Published 9 February 2024. doi:10.1093/rheumatology/keae085

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.